Karo Pharma takes aim at Europe

In a short period of time Karo Pharma has, through expanded strategic acquisitions and organic growth, become established as one of the leading specialty pharma companies in the Nordics. Our ambition is to offer products that improve people’s health and quality of life. We have a commercial focus and specialize on the sales and marketing of prescription drugs (Rx) and over the counter (OTC) products for consumers. Our products are available in over 30 countries.

At Karo Pharma we strive to be cost-conscious and opportunistic. The company is growing organically with established brands that have stable cash flows, as well as through acquisitions and investments in innovative projects with low development risk and short time to market. It is a strategy that has given us solid profitability the past few years and positions us as an attractive partner now that we aim to strengthen our presence in Europe and the rest of the world.

Press releases

14 August, 2019

Jon Johnsson appointed new CFO of Karo Pharma

Karo Pharma Aktiebolag (publ) (“Karo Pharma”) has appointed Jon Johnsson as the new CFO of Karo Pharma, replacing Mats-Olof Wallin,…
19 July, 2019

Clarification of the statement in the interim report published 19 July 2019 regarding the rights issue with pre-emptive rights

Karo Pharma Aktiebolag (”Karo Pharma”) today published its interim report for the period January – June 2019. On page 2…
21 June, 2019

Karo Pharma acquires Trimb for MSEK 3,400 and intends to carry out a rights issue of approximately MSEK 1,500

Karo Pharma AB (publ) (the ”Company” or ”Karo Pharma”) has today acquired all the shares of Trimb Holding AB (“Trimb”)…

 See all press releases

Reports

19 July, 2019

INTERIM REPORT JANUARY – JUNE 2019

THE PERIOD AND THE SECOND QUARTER
26 April, 2019

INTERIM REPORT THE FIRST QUARTER 2019

· Net sales amounted to MSEK 420.8 (267.1). This corresponds to an increase of 58%. The growth is attributable to…
9 April, 2019

Karo Pharma publishes the 2018 annual report

Karo Pharma publishes its annual report for 2018. Today, on 9 April 2019, Karo Pharma is publishing its annual report…

 See all reports

About Karo Pharma

Karo Pharma is a profitable and rapidly growing specialty pharma company that contributes to better health and improved quality of life.
Read more

Partnership

We have an opportunistic attitude to partnerships and acquisitions of companies and brands that suit our product portfolio, organization and business strategy.
Read more

Investors

We create stockholder value through regular acquisitions and investments in established products with stable earning potential.
Read more

Products

Locobase

Locobase

Locobase is a well-established skincare brand, recommended by health care professionals and pharmacy staff. Locobase is an international brand being sold in around 40 countries with a strong position mainly on the Nordic market. Locobase is clinically proven to be gentle to sensitive skin and highly suitable for eczema-prone skin. Locobase is available as Repair,...

Virusseptin

Viruseptin

Viruseptin is a dual-acting cold spray that can be used for prevention and treatment of nasal and pharyngeal infections. Viruseptin effectively prevents viruses from spreading and can, if the cold has already broken out, shorten the disease period and reduce the risk of a recurring infection. Viruseptin is the first cold spray that has had...

Paracet

Paracet is Norway’s #1 OTC product (Farmastat/Nielsen, 2017) against headache and pain and is used for short term treatment of mild to moderate pains such as headache, toothache, menstrual pain, muscle- and joint pain. Paracet also decreases fever during a cold or a flu. Paracet is available in different drug forms and strengths, depending on...

View more products